Cure My Disease

Don't miss your cure!

 Log in / Sign up

New combo shows promise in Tough-to-Treat head and neck cancer

NCT ID NCT04338399

Disease control Sponsor: Adlai Nortye Biopharma Co., Ltd. Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether adding the drug buparlisib to standard chemotherapy (paclitaxel) helps people with advanced head and neck cancer live longer. About 487 adults whose cancer had returned or spread and who had already tried other treatments took part. The goal was to see if the combination improves survival and quality of life compared to chemotherapy alone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 3

Large-scale testing in a bigger group. Usually the last step before a treatment can be approved.

Participants

487 people

The number who actually took part.

Started

Dec 2020

Finished

Nov 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥18 years old. 2. Able to provide informed consent obtained before any trial related activities and according to local guidelines. 3. Patient has histologically and/or cytologically-confirmed HNSCC. 4. Patient has archival or new tumor tissue for the analysis of biomarkers and confirmation of HPV status (if unknown). One tumor block (preferred) or a recommended minimum of 5 unstained slides for patients with known HPV status (for tumor DNA characterization) or a recommended minimum of 10 slides for patients whose HPV status is unknown (5 slides for HPV testing plus 5 slides needed for biomarker testing). Enrollment in the study is contingent on confirmation of the availability of an adequate amount of tumor tissue, except in rare special circumstances, which must be reviewed and approved by the sponsor. 5. Patient has either progressive or recurrent disease after treatment with PDL1/PD1 based therapy for recurrent or metastatic disease: 1. PDLl/PD1 therapy alone for metastatic (monotherapy) disease 2. PDL1/PD1 in combination with chemotherapy for metastatic and recurrent disease 3. PDL1/PD1 used for metastatic disease, after or prior to receiving a platinum agent for locally advanced or metastatic disease. 6. 6\. Patient has received no more than two prior lines of systemic treatment for HNSCC (single agent chemotherapy used as a radiosensitizer is not counted as a prior line of therapy). 7. Patient has measurable disease as determined per RECIST version 1.1. If the only site of measurable disease is a previously irradiated lesion, documented progression of disease and a four-week period since radiotherapy completion is required. 8. Patient has adequate bone marrow function and organ function as shown by the following: 1. Absolute neutrophil count (ANC) ≥1.5 x 109/L. 2. Hemoglobin ≥9 g/dL (which may be reached by transfusion). 3. Platelets ≥100 x 109/L (which may be reached by transfusion). 4. International normalized ratio (INR) ≤1.5. 5. Calcium (corrected for serum albumin) within normal limits (WNL) or ≤ grade 1 severity according to NCI-CTCAE version 5.0 if judged clinically not significant by the Investigator. Patients concomitantly taking bisphosphonates or denosumab for calcium correction are eligible. 6. Normal potassium and magnesium levels. 7. Alanine aminotransferase (AST) and aspartate aminotransferase (ALT) ≤ 1.5 x upper limit of normal (ULN) or \< 3.0 x ULN if liver metastases are present. 8. Total serum bilirubin ≤ ULN or ≤ 1.5 x ULN if liver metastases are present; or total bilirubin ≤ 3.0 x ULN with direct bilirubin below or within normal range in patients with well documented Gilbert's Syndrome. Gilbert's syndrome is defined as presence of episodes of unconjugated hyperbilirubinemia with normal results from cells blood count (including normal reticulocyte count and blood smear), normal liver function test results, and absence of other contributing disease processes at the time of diagnosis. 9. Serum creatinine ≤ 1.5 x ULN or calculated and directly measured creatinine clearance (CrCL) \> 30 mL/min. 10. Haemoglobin A1c (glycosylated hemoglobin; HbA1c) ≤8%. 9. Patient has Eastern Cooperative Oncology Group (ECOG) performance status ≤1. 10. Patient is able to swallow and retain oral medication. Patients able to swallow oral medication but mostly self-nourished through gastric or jejunal feeding tube are eligible. 11. Patients must apply highly effective contraception during and throughout the study, as well after the final dose of study treatment Exclusion Criteria: Patients meeting any of the following criteria will not be eligible for participation in the study: 1. Patient has received previous treatment with any protein kinase B (PKB/AKT), mammalian target of rapamycin (mTOR) inhibitors, or phosphatidylinositol 3 kinase (PI3K) pathway inhibitors. 2. Patient received treatment with a taxane as part of prior treatment for metastatic disease. 3. Patient has symptomatic central nervous system (CNS) metastases. Patients with asymptomatic CNS metastases may participate in this study. Patient must have completed any prior local treatment for CNS metastases ≥ 28 days prior to the start of study treatment (including radiotherapy) and must be on a stable low dose of corticosteroid therapy. Radiosurgery must have been completed at least 14 days prior to start of study treatment. 4. Patient has received wide field radiotherapy ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study treatment or who have adverse events which have not recovered to grade 1 or better from previous chemotherapy treatment (except alopecia, autoimmune endocrine events must be stable and controlled). 5. Patient has grade ≥ 2 neuropathy, colitis, pneumonitis, , and uncontrolled endocrinopathies (e.g., hypothyroidism, diabetes with hemoglobin A1c \> 8%) from previous treatment 6. Patient has had major surgery within 14 days prior to starting study treatment or has not recovered from major side effects. 7. Patient is currently receiving increasing or chronic treatment (\>5 days) with corticosteroids or another immunosuppressive agent. The following uses of corticosteroids are permitted: single doses; standard premedication for paclitaxel, topical applications (e.g., rash), inhaled sprays (e.g., obstructive airways diseases), eye drops, or local injections (e.g., intra-articular), or \< 10 mg prednisolone or equivalent. 8. Patient is being treated at start of study treatment with any of the following drugs: 1. Drugs known to be strong or moderate inhibitors or inducers of isoenzyme cytochrome P450 3A4 (CYP3A4) including herbal medications (see Table 16). 2. Drugs with a known risk of inducing Torsades de Pointes. Note: The patient must have discontinued strong inducers for at least one week and must have discontinued strong inhibitors before the treatment is initiated. Switching to a different medication prior to starting study treatment is allowed. 9. Patient is currently receiving warfarin or other coumarin-derived anti-coagulant, for treatment, prophylaxis, or otherwise. Therapy with heparin, low molecular weight heparin (LMWH), fondaparinux or new oral anticoagulants (NOACs) is allowed. 10. Patient has a known hypersensitivity and/or contraindication to paclitaxel, standard premedication for paclitaxel, or other products containing Cremophor®. 11. Patient has other concurrent severe and/or uncontrolled medical conditions that would, in the Investigator's judgment, contraindicate patient participation in the clinical study (e.g., active or uncontrolled severe infection, chronic active hepatitis, immunocompromised, acute or chronic pancreatitis, uncontrolled high blood pressure, interstitial lung disease, etc). 12. Patient has a known history of human immunodeficiency virus (HIV) infection (testing not mandatory). 13. Patient has any of the following cardiac abnormalities: 1. Symptomatic congestive heart failure within 12 months of the screening period. 2. History of documented congestive heart failure (New York Heart Association functional classification III-IV) or documented cardiomyopathy and left ventricular ejection fraction (LVEF) \<50% as determined by multiple gated acquisition (MUGA) scan or echocardiogram (ECHO). 3. Myocardial infarction ≤six months prior to enrollment. 4. Unstable angina pectoris. 5. Serious uncontrolled cardiac arrhythmia. 6. Symptomatic pericarditis. 7. QT interval corrected according to the formula of Fridericia (QTcF) \> 450 msec for males and \> 470 msec for females, on the screening electrocardiogram (ECG). 8. Currently receiving treatment with medication that has a known risk to prolong the QT interval or inducing Torsades de Pointes, and the treatment cannot be discontinued or switched to a different medication prior to starting study treatment. 14. Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of study treatment (e.g., ulcerative diseases, uncontrolled nausea, vomiting, diarrhea, malabsorption syndrome, or small bowel resection). 15. Patient has a medically documented history of or active major depressive episode, bipolar disorder (I or II), obsessive-compulsive disorder, schizophrenia, a history of suicidal attempt or ideation, or homicidal ideation (e.g., risk of doing harm to self or others), or active severe personality disorders (defined according to the Diagnostic and Statistical Manual of Mental Disorders Fifth Edition \[DSM-V\]) are not eligible. Note: For patients with psychotropic treatments ongoing at baseline, the dose and the schedule should not be modified within the previous six weeks prior to start of study treatment. 16. Patient has other prior or concurrent malignancy except for the following: adequately treated basal cell or squamous cell skin cancer, or other adequately treated in situ cancer, early gastric or GI cancer resected completely by endoscopy procedures or any other cancer from which the patient has been disease free for ≥ 3years. 17. Patient has a history of non-compliance to any medical regimen or inability to grant consent. 18. Patient is concurrently using or has used another approved or investigational cancer agent within 4 weeks of randomization. 19. Patient is pregnant or nursing (lactating). Patients with elevated human chorionic gonadotrophin (hCG) at baseline that is judged to be related to the tumor are eligible if hCG levels do not show the expected doubling when repeated five to seven days later, or pregnancy has been ruled out by vaginal ultrasound. 20. Patient has received a live vaccine within 30 days of planned start of study therapy. Note: Seasonal influenza vaccines for injection are generally inactivated flu vaccines and are allowed; however intranasal influenza vaccines (eg, Flu-Mist®) are live attenuated vaccines, and are not allowed. Non-live COVID vaccinations or boosters should not occur within 30 days of study start.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Head and neck cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

head and neck cancer Head and Neck Neoplasms head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Head and neck cancer

Contacts and locations

Locations

  • A.O. S. Croce e Carle

    Cuneo, 12100, Italy

  • A.O.U. "Maggiore della Carita"- S.C.D.U Oncologiac

    Novara, 28100, Italy

  • AO Card. G. Panico

    Tricase, 73039, Italy

  • AOU San Giovanni di Dio e Ruggi D'Aragona, Università degli Studi di Salerno

    Salerno, 84131, Italy

  • ASST Spedali Civili Brescia

    Brescia, 25123, Italy

  • ASST Valtellina e Alto Lario - UOC Oncologia Medica Ospedale di Sondrio

    Sondrio, 23100, Italy

  • Affiliated Cancer Hospital of Chongqing University

    Chongqing, 400000, China

  • Affiliated Cancer Hospital of Guangzhou Medical University

    Guangzhou, 510095, China

  • Aichi Cancer Center

    Nagoya, 464-8681, Japan

  • Ajou University Hospital

    Suwon, 16499, South Korea

  • Anhui Provincial Cancer Hospital

    Hefei, 230031, China

  • Asan Medical Center

    Seoul, 5505, South Korea

  • Azienda Ospedaliera San Paolo Polo Universitario

    Milan, 20142, Italy

  • Azienda Ospedaliera Universitaria Integrata Verona

    Verona, 37126, Italy

  • Azienda Ospedaliera Universitaria S.Orsola-Malpighi

    Bologna, 40138, Italy

  • Azienda Ospedaliera Universitaria Senese Policlinico Le Scotte

    Siena, 53100, Italy

  • Azienda Ospedaliero Universitaria Careggi - Firenze

    Florence, 50134, Italy

  • Azienda Ospedaliero Universitaria Policlinico "Paolo Giaccone" U.O.C. Oncologia Medica

    Palermo, 90127, Italy

  • Azienda Ospedaliero Universitaria di Parma

    Parma, 43126, Italy

  • Azienda Sanitaria Universitaria Integrata di Udine

    Udine, 33100, Italy

  • Beatson Oncology Centre

    Glasgow, G12 0YN, United Kingdom

  • Beijing Tongren Hospital

    Beijing, 100176, China

  • CHP Saint-Grégoire

    Saint-Grégoire, 35760, France

  • CHUM

    Montreal, H2X 0C2, Canada

  • Cancer Hospital affiliated to Guangxi Medical University

    Naning, 530021, China

  • CancerCare Manitoba

    Winnipeg, R3E 0V9, Canada

  • Centre Franois Baclesse

    Caen, 14000, France

  • Centre Leon Berard

    Lyon, 69008, France

  • Centre hospitalier Universitaire de Bordeaux

    Bordeaux, 33075, France

  • Centro de Investigacion Pergamino SA - Clinica Pergamino S.A.

    Buenos Aires, B2700CPM, Argentina

  • Centro para la Atencion Integral del Paciente Oncologico - CAIPO

    San Miguel de Tucumán, T4000GTB, Argentina

  • Chang Gung Memorial Hospital-KaohSiung

    Kaohsiung City, 833, Taiwan

  • Chang Gung Memorial Hospital-LinKou

    Taoyuan, 33342, Taiwan

  • Changhua Christian Hospital

    Changhua, 500, Taiwan

  • Chi Mei Medical Center Liouying

    Tainan, 73657, Taiwan

  • City of Hope

    Duarte, California, 91010, United States

  • Clinica Universidad de Navarra

    Madrid, 28027, Spain

  • Clinique CHC MontLégia

    Liège, 4000, Belgium

  • Clinique Hartmann

    Neuilly-sur-Seine, 92200, France

  • Clinique Saint-Pierre dOttignies CSPO

    Ottignies, 1340, Belgium

  • Complejo Hospitalario de Jaen

    Jaén, 23007, Spain

  • Duke University Medical Center

    Durham, North Carolina, 27710, United States

  • Edinburgh Cancer Center

    Edinburgh, EH4 2XU, United Kingdom

  • Emory University

    Atlanta, Georgia, 30322, United States

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Franziskus Hospital

    Georgsmarienhütte, 49124, Germany

  • Fundacion CORI para la Investigacion y Prevencion del Cáncer

    La Rioja, F5300COE, Argentina

  • Fundacion Cenit para la Investigacion en Neurociencias

    Buenos Aires, 1125, Argentina

  • Fundacion Oncologico de Galicia Jos Antonio Quiroga y Pieyro

    A Coruña, 15009, Spain

  • Gachon University Gil Medical Center

    Incheon, 21565, South Korea

  • HNO-Klinik des Universitats-Klinikums Giessen

    Giessen, 35392, Germany

  • Hannover Medical School

    Hanover, 30625, Germany

  • Henan Cancer Hospital

    Zhengzhou, 450000, China

  • Henry Ford Health System

    Detroit, Michigan, 48202, United States

  • Hokkaido University Hospital

    Sapporo, 060-8648, Japan

  • Hollings Cancer Center

    Charleston, South Carolina, 29425, United States

  • Hope Cancer Center, UT Health East Texas

    Tyler, Texas, 75701, United States

  • Hopital La Pitie Salpetriere

    Paris, 75013, France

  • Hopital Tenon

    Paris, 75970, France

  • Hopital de la Timone

    Marseille, 13005, France

  • Hospital Clinic Barcelona

    Barcelona, 08036, Spain

  • Hospital Clinico Universitario Valencia - INCLIVA

    Valencia, 46010, Spain

  • Hospital Clinico Universitario Virgen de la Arrixaca

    Madrid, 30120, Spain

  • Hospital Duran i Reynals - Institut Catala dOncologia ICO

    L'Hospitalet de Llobregat, 08908, Spain

  • Hospital General Universitario Gregorio Maran

    Madrid, Spain

  • Hospital Puerta de Hierro- Majadahonda

    Majadahonda, 28220, Spain

  • Hospital Regional de Malaga

    Málaga, 29010, Spain

  • Hospital Reina Sofia

    Córdoba, 14004, Spain

  • Hospital Universitario 12 de Octubre

    Madrid, 28041, Spain

  • Hospital Universitario Fundacion Jimenez Diaz

    Madrid, 28040, Spain

  • Hospital Universitario La Paz

    Madrid, 28046, Spain

  • Hospital Universitario Lucus Augusti

    Lugo, 27003, Spain

  • Hospital Universitario Marques de Valdecilla

    Santander, 39008, Spain

  • Hospital Universitario Miguel Servet

    Zaragoza, 50009, Spain

  • Hospital Universitario Ramon y Cajal

    Madrid, 28034, Spain

  • Hospital Universitario Santiago de Compostela

    Santiago de Compostela, 15706, Spain

  • Hospital Universitario Severo Ochoa

    Leganés, 28911, Spain

  • Hospital Universitario de Burgos

    Burgos, 09006, Spain

  • Hospital de Navarra

    Pamplona, 31008, Spain

  • Hospital de la Santa Creu i Sant Pau

    Barcelona, 08025, Spain

  • Hunan Cancer Hospital

    Changsha, 410000, China

  • Hyogo Cancer Center

    Akashi-shi, 673-8558, Japan

  • Hôpital St-Louis

    Paris, 75010, France

  • INT IRCCS Fondazione G.Pascale

    Naples, 80131, Italy

  • IONC SRL- Instituto Oncológico de Córdoba

    Córdoba, X5002HWE, Argentina

  • IRCCS - Istituto Scientifico Romagnolo per la Cura e lo Studio dei Tumori

    Cesena, Italy

  • IRCCS Istituto Clinico Humanitas

    Rozzano, 20089, Italy

  • IRCCS Maugeri Pavia

    Pavia, 27100, Italy

  • Institut Catala d Oncologia Badalona

    Badalona, 08916, Spain

  • Institut de cancerologie de Lorraine

    Vandœuvre-lès-Nancy, 54500, France

  • Institut regional du Cancer de Montpellier

    Montpellier, 34298, France

  • Instituto Valenciano de Oncologia

    Valencia, 46009, Spain

  • Instituto de Investigaciones Metabólicas (IDIM) // Instituto de Investigaciones Metabólicas S.A.

    Ciudad Autonoma de Buenos Aire, C1012AAR, Argentina

  • Istituto Nazionale dei Tumori

    Milan, 20133, Italy

  • Istituto di Candiolo IRCCS

    Candiolo, 10060, Italy

  • Kagawa University Hospital

    Kita-gun, 761-0793, Japan

  • Karmanos Cancer Institute

    Detroit, Michigan, 48201, United States

  • Kindai University Hospital

    Osaka Sayama-shi, 589-8511, Japan

  • Kobe University Hospital

    Kobe, 650-0017, Japan

  • Korea University Anam Hospital

    Seoul, 2841, South Korea

  • Korea University Guro Hospital

    Seoul, 8308, South Korea

  • Kosin University Gospel Hospital

    Busan, 49267, South Korea

  • Kyushu University Hospital

    Fukuoka, 812-8582, Japan

  • LHopital prive du Confluent Nantes

    Nantes, 44277, France

  • Marienkrankenhaus Hamburg

    Hamburg, 22045, Germany

  • Moffitt Cancer Center

    Tampa, Florida, 33612, United States

  • Montefiore Medical Center

    The Bronx, New York, 10461, United States

  • NYU Langone

    New York, New York, 10016, United States

  • Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie

    Gliwice, 44-102, Poland

  • Narodowy Instytut Onkologii im. Marii Skłodowskiej-Curie

    Warsaw, 02-781, Poland

  • National Cancer Center Hospital

    Chūōku, 104-0045, Japan

  • National Cheng Kung University Hospital

    Tainan, 704017, Taiwan

  • National Hospital Organization Shikoku Cancer Center

    Matsuyama, 791-0280, Japan

  • National University Corporation Tohoku University, Tohoku University Hospital

    Sendai, 980-8574, Japan

  • Northwestern University

    Chicago, Illinois, 60611, United States

  • Norton Cancer Institute

    Louisville, Kentucky, 40202, United States

  • Orszagos Onkologiai Intezet

    Budapest, 1122, Hungary

  • Princess Alexandra Hospital

    Brisbane, 4102, Australia

  • Queen Mary Hospital

    Hong Kong, Hong Kong

  • Saitama Medical University International Medical Center

    Hidaka, 350-1298, Japan

  • Seoul National University Bundang Hospital

    Seongnam-si, 13620, South Korea

  • Shandong Provincial Tumor Hospital

    Jinan, 250000, China

  • Shanghai Dongfang Hospital

    Shanghai, 310115, China

  • Shizuoka Cancer Center

    Shizuoka, 411-8777, Japan

  • Showa University Hospital

    Shinagawa-Ku, 142-8666, Japan

  • Sichuan Cancer Hospital

    Chengdu, 610042, China

  • Stony Brook University Medical Center

    Stony Brook, New York, 11794, United States

  • Sun Yat-sen University Cancer Center

    Guangzhou, 510000, China

  • Taichung Veterans General Hospital

    Taichung, 40705, Taiwan

  • Taipei Veterans General Hospital

    Taipei, 11217, Taiwan

  • The Cancer Institute Hospital of JFCR

    Kōtoku, 135-8550, Japan

  • The Catholic University of Korea Seoul ST. Mary's Hospital

    Seoul, 6591, South Korea

  • The Fifth Affiliated Hospital of Sun Yat-sen University

    Zhuhai, 519000, China

  • The First Affiliated Hospital of Bengbu Medical College

    Bengbu, 233004, China

  • The First Affiliated Hospital of CQMU

    Chongqing, 400042, China

  • The Royal Marsden NHS Foundation Trust

    London, SW3 6JJ, United Kingdom

  • The Royal Marsden NHS Foundation Trust - Sutton

    Sutton, SM2 5PT, United Kingdom

  • Tianjin Cancer Hospital

    Tianjin, 300202, China

  • Tolna Megyei Balassa Janos Korhaz

    Szekszárd, 7100, Hungary

  • UNIVERSITÄTSMEDIZIN Mainz III. Klinik/Poliklinik

    Mainz, 55131, Germany

  • UPMC Hillman Cancer Center

    Pittsburgh, Pennsylvania, 15232, United States

  • Uniklinik RWTH Aachen

    Aachen, 52074, Germany

  • Universitaetsklinikum Bonn

    Bonn, 53127, Germany

  • Universitair Ziekenhuis Brussel

    Jette, 1090, Belgium

  • Universitair Ziekenhuis Gent UZ Gent

    Ghent, 9000, Belgium

  • Universitatsklinikum Hamburg Eppendorf

    Hamburg, 20246, Germany

  • Universitatsklinikum Leipzig

    Leipzig, 04103, Germany

  • Universitatsmedizin Greifswald - KoR

    Greifswald, 17489, Germany

  • University College London Hospitals

    London, NW1 2BU, United Kingdom

  • University Hospital Essen

    Essen, 45147, Germany

  • University of Cincinnati Cancer Center

    Cincinnati, Ohio, 45219, United States

  • University of Kentucky

    Lexington, Kentucky, 40536, United States

  • University of Michigan

    Ann Arbor, Michigan, 48109, United States

  • University of Pecs Department of Oncotherapy

    Pécs, 7624, Hungary

  • Vall dHebron Institute of Oncology (VHIO)

    Barcelona, 08035, Spain

  • Valme Hospital Medical Oncology Department

    Seville, 41014, Spain

  • Washington University School of Medicine

    St Louis, Missouri, 63130, United States

  • West Cancer Center

    Germantown, Tennessee, 38138, United States

  • Xiangya Hospital Central South University

    Changsha, 410000, China

  • Yale University, Yale Cancer Center

    New Haven, Connecticut, 06511, United States

  • Yunnan Cancer Hospital

    Kunming, 650000, China

  • Zhejiang Cancer Hospital

    Hangzhou, 310022, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.